Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

被引：10
|
作者：
Komrokji, Rami S. [1 ]
Singh, Avani M. [2 ,3 ]
Al Ali, Najla [1 ]
Chan, Onyee [1 ]
Padron, Eric [1 ]
Sweet, Kendra [1 ]
Kuykendall, Andrew [1 ]
Lancet, Jeffrey E. [1 ]
Sallman, David A. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Hematol Oncol, Tampa, FL 33620 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 11期
关键词：
D O I：
10.1038/s41408-022-00744-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] FAVORABLE OUTCOMES WITH TUMOR BURDEN REDUCTION WITH HYPOMETHYLATING AGENTS BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLNATATION FOR PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME
    Park, S. W.
    Kim, J. Y.
    Lee, Y. J.
    Sohn, S. K.
    Ahn, J. S.
    Kim, H. J.
    Shin, H. J.
    Lee, W. S.
    Lee, S. M.
    Joo, Y. D.
    Kim, H.
    Lee, H. S.
    Kim, Y. S.
    Cho, Y. Y.
    Moon, J. H.
    HAEMATOLOGICA, 2016, 101 : 504 - 504
  • [42] Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2021, 138
  • [43] Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome
    Niederwieser, Christian
    Kroeger, Nicolaus
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (04)
  • [44] Hematopoietic cell transplantation in Myelodysplastic Syndrome after Failure of Hypomethylating Agents
    Festuccia, M.
    Deeg, J.
    Scott, B.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S75 - S75
  • [45] Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome
    Takayuki Ishikawa
    International Journal of Clinical Oncology, 2014, 19 : 10 - 15
  • [46] Predictive Factors of Treatment Response to Hypomethylating Agents in Patients with Myelodysplastic Syndrome
    Wu, Ping
    Du, Xin
    Weng, Jianyu
    Deng, Chengxin
    Geng, Suxia
    Lu, Zesheng
    Lai, Peilong
    Huang, Xin
    Luo, Chengwei
    BLOOD, 2015, 126 (23)
  • [47] Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome
    Ishikawa, Takayuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (01) : 10 - 15
  • [48] Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
    Hu, Xiaoyan
    Li, Lin
    Nkwocha, Jewel
    Sharma, Kanika
    Zhou, Liang
    Grant, Steven
    HEMATOLOGY REPORTS, 2023, 15 (01) : 91 - 100
  • [49] Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
    Braish, Julie
    Montalban-Bravo, Guillermo
    Ravandi, Farhad
    Short, Nicholas J.
    Kadia, Tapan M.
    Ohanian, Maro
    Chien, Kelly S.
    Masarova, Lucia
    Sasaki, Koji
    Yilmaz, Musa
    Daver, Naval
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2024, 144 : 3209 - 3210
  • [50] Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome
    Pierola, Ana Alfonso
    Montalban-Bravo, Guillermo
    Takahashi, Koichi
    Feng Wang
    Song Xingzhi
    Jabbour, Elias J.
    Kadia, Tapan M.
    Ravandi, Farhad
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Daver, Naval G.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Konopleva, Marina
    Bueso-Ramos, Carlos E.
    Patel, Keyur
    Futreal, Andrew
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2016, 128 (22)
12345